Short‐ and long‐term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism

Background  The long‐term efficacy of somatostatin analogues on insulinomas has not been studied.

[1]  I. Gallen,et al.  Possible functional regression of insulinoma with prolonged octreotide , 2001, Postgraduate medical journal.

[2]  V. Marks,et al.  Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon , 1995, Clinical endocrinology.

[3]  T. de Baère,et al.  Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. , 2001, European journal of cancer.

[4]  J. Farndon,et al.  Diazoxide in the management of patients with insulinoma , 1986, World Journal of Surgery.

[5]  W. Hopfenmüller,et al.  Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. , 1997, European journal of endocrinology.

[6]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[7]  U. Kumar,et al.  Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. , 1996, Endocrinology.

[8]  Y. Oda,et al.  The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: Report of a case , 2000, Surgery Today.

[9]  V. Go,et al.  Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut , 1989 .

[10]  T. Yoshimoto,et al.  Glucose-responsive and octreotide-sensitive insulinoma. , 2006, Internal medicine.

[11]  Y. Takeda,et al.  Medical treatment of benign insulinoma using octreotide LAR: a case report. , 2007, Endocrine journal.

[12]  H. Gjessing,et al.  Metabolic remission with octreotide in patients with insulinoma , 1994, Journal of internal medicine.

[13]  E. Rubin.  Hypoglycemic disorders. , 1995, The New England journal of medicine.

[14]  R. Jensen,et al.  Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors , 1989, Digestive Diseases and Sciences.

[15]  G. Gill,et al.  Diazoxide treatment for insulinoma: a national UK survey. , 1997, Postgraduate medical journal.

[16]  E. Menis,et al.  111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients , 1997, Journal of endocrinological investigation.

[17]  G. Lasio,et al.  Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? , 2003, The Journal of clinical endocrinology and metabolism.

[18]  E. Krenning,et al.  Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J. Bertherat,et al.  Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. , 2003, The Journal of clinical endocrinology and metabolism.

[20]  W. Young,et al.  Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  H. Imura,et al.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. , 1993, Biochemical and biophysical research communications.

[22]  T. Katabami,et al.  Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma. , 2005, Endocrine journal.

[23]  T. Shawker,et al.  A prospective examination of octreotide‐induced gall‐bladder changes in acromegaly , 1992, Clinical Endocrinology.

[24]  T. Kondo,et al.  A case of hyperinsulinemia of undetermined origin, successfully treated with long-acting octreotide. , 2005, Endocrine journal.

[25]  J. Friedman,et al.  Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin Receptor* , 1997, The Journal of Biological Chemistry.

[26]  W. Saeger,et al.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. , 1994, The Journal of clinical endocrinology and metabolism.

[27]  W. Lems,et al.  Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). , 1989, Acta endocrinologica.

[28]  P. Rochaix,et al.  Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. , 2005, European journal of endocrinology.

[29]  Y. Hao,et al.  DEPLETION OF HEAT SHOCK PROTEIN-70 (HSP70) CAUSES APOPTOSIS IN PANCREATIC CANCER CELLS , 2005 .

[30]  B. Glaser,et al.  Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995. , 1990, Israel journal of medical sciences.

[31]  S. Lamberts,et al.  Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. , 1990, Cancer research.

[32]  A. Hirose,et al.  Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients. , 2006, Endocrine journal.

[33]  C. Newman.  Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238] , 1995 .

[34]  N. Woodhouse,et al.  The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review. , 1988, Hormone research.

[35]  G. Tolis,et al.  Medical Treatment of Acromegaly: Comorbidities and Their Reversibility by Somatostatin Analogs , 2006, Neuroendocrinology.

[36]  M. Milione,et al.  Complete Clinical Remission and Disappearance of Liver Metastases after Treatment with Somatostatin Analogue in a 40-Year-Old Woman with a Malignant Insulinoma Positive for Somatostatin Receptors Type 2 , 2006, Hormone Research in Paediatrics.